Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia

P. J. Hengeveld, J. Schilperoord-Vermeulen, M. Y. van der Klift, J. M.N. Dubois, P. M. Kolijn, F. G. Kavelaars, M. Rijken, J. A. Dobber, K. Nasserinejad, S. Kersting, P. E. Westerweel, A. P. Kater, A. W. Langerak, M. D. Levin*

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

5 Downloads (Pure)
Original languageEnglish
Article number102
JournalBlood Cancer Journal
Issue number1
Publication statusPublished - 4 Jul 2023

Bibliographical note

The authors would like to thank all patients, their families, study monitors and investigators that participated in the HOVON-139/GIVE trial. The HOVON-139/GIVE trial was funded by F Hoffmann-La Roche (ML29995), who had the opportunity to review and comment on this paper.

Cite this